Influence of roxadustat combined with rHuEPO on iron metabolism,nutritional status and serum calcium in patients with renal anemia receiving hemodialysis
Objective To investigate the influence of roxadustat combined with recombinant human erythropoietin(rHuEPO)on iron metabolism,nutritional status and serum calcium in patients with renal anemia undergoing hemodialysis.Methods A total of 94 patients with renal anemia receiving hemodialysis in the Affiliated Hospital of Tangshan Vocational and Technical College from January 2023 to January 2024 were enrolled in this study and divided into the observation group(n=47)and control group(n=47)with the random number table method.The patients in the control group were treated with rHuEPO and those in the observation group with roxadustat combined with rHuEPO.The iron metabolism function,anemia indicators,calcium-phosphorus metabolism,inflammatory factors and incidence rates of adverse reactions were compared between the two groups.Results After treatment for 3 months,the levels of serum ferritin receptor,serum calcium,serum phosphorus,calcium-phosphorus product,C-reactive protein,interleukin-6 and tumor necrosis factor-α were(15.13±2.46)mg·L-1,(1.94±0.33)mmol·L-1,(1.83±0.41)mmol·L-1,(44.02±1.68),(6.47±1.52)mg·L-1,(67.37±2.83)ng·L-1,and(115.53±5.34)ng·L-1 in the observation group,which were significantly lower than those of(17.32±2.34)mg·L-1,(2.12±0.31)mmol·L-1,(2.11±0.35)mmol·L-1,(55.47±1.35),(7.38±1.43)mg·L-1,(69.59±2.64)ng·L-1,and(119.37±6.18)ng·L-1 in the control(t=4.422,2.725,3.561,36.422,2.989,3.932,3.223,all P<0.05).The levels of serum ferritin,transferrin saturation,hemoglobin,hematocrit and red blood cell count after 3 months of treatment in the observation group were(243.52±6.73)μg·L-1,(33.29±2.43)%,(116.87±3.18)g·L-1,(36.46±2.63)×1012 and(3.39±0.61)%,which were significantly higher than those of(238.64±6.89)μg·L-1,(31.35±2.61)%,(113.35±3.27)g·L-1,(32.52±2.76)×1012,and(2.73±0.57)%in the control(t=3.474,3.730,5.291,7.085,5.420,all P<0.05).However,the total incidence rate of adverse reactions was 14.89%in the observation group and 12.77%in the control(P>0.05).Conclusion Roxadustat combined with rHuEPO in treatment of patients with renal anemia receiving hemodialysis can significantly enhance iron metabolism function,improve nutritional status and calcium-phosphorus metabolism level,and relieve anemia symptoms and inflammatory response.Meanwhile,it is of high safety.
HemodialysisRenal anemiaRoxadustatRecombinant human erythropoietinIron metabolismNutritional status
NETL
NSTL
万方数据
